trending Market Intelligence /marketintelligence/en/news-insights/trending/ukylep1a2y7kkz_cn5xfyq2 content esgSubNav
In This List

Knight Therapeutics secures Canadian rights to Ardelyx drug

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Knight Therapeutics secures Canadian rights to Ardelyx drug

Ardelyx Inc. sold the Canadian rights to its medicine tenapanor to Knight Therapeutics Inc.

The medicine has been evaluated in a late-stage trial to treat irritable bowel syndrome with constipation and is being studied in a second phase 3 study for hyperphosphatemia, which causes an abnormally elevated level of phosphate in the blood.

Fremont, Calif.-based Ardelyx will receive C$25 million for the rights. The amount includes an undisclosed up-front payment from Montreal-based Knight Therapeutics.

In December 2017, Ardelyx sold the rights to develop and commercialize the drug in China to Shanghai Fosun Pharmaceutical (Group) Co. Ltd. for an up-front payment of $12 million.